Previous close | 7.01 |
Open | 7.01 |
Bid | 0.00 |
Ask | 0.00 |
Strike | 800.00 |
Expiry date | 2024-06-21 |
Day's range | 7.01 - 7.01 |
Contract range | N/A |
Volume | |
Open interest | N/A |
First quarter 2024 revenues decreased 1% to $3.15 billion versus first quarter 2023; excluding RonapreveTM(a)(b), revenues increased 7%First quarter 2024 Dupixent® global net sales (recorded by Sanofi) increased 24% to $3.08 billion versus first quarter 2023First quarter 2024 U.S. net sales for EYLEA® HD and EYLEA® were $1.40 billion, including $200 million from EYLEA HDFirst quarter 2024 Libtayo® global net sales increased 45% to $264 million versus first quarter 2023First quarter 2024 GAAP dil
Let's look at five large-cap pharma/biotech companies slated to release quarterly results this week.
An increase in profits from Dupixent and further uptake of Eylea HD are likely to have aided Regeneron (REGN) in partially offsetting the decline in Eylea sales.